Skip to main content
Premium Trial:

Request an Annual Quote

3M Developing Nucleic Acid Test Kits with Lumora's BART Technology

NEW YORK (GenomeWeb News) – 3M has entered into a joint development and licensing deal for use of Lumora's BART technology in developing nucleic acid test kits, the firms announced today.

Financial and other details of the agreement were not disclosed.

BART, which stands for Bioluminescent Assay in Real-Time, is a novel reporter system for use with isothermal nucleic acid amplification technologies as a tool in molecular diagnostics. In a statement, UK-based Lumora said that it is looking for other collaborative development and licensing partnerships "to bring its core technology to market in industrial sectors and clinical in vitro diagnostic applications."

In May the company announced it had raised about $2.1 million in second-stage funding, which would be used to accelerate its move in the clinical molecular diagnostics space with the BART technology.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.